Navigation Links
Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
Date:9/4/2007

ients have had a maximum Grade 1 QTc interval prolongation, and 7 patients a maximum Grade 2; the increases were clinically asymptomatic and not associated with AEs or dose reduction or delay. One patient who experienced an event of asymptomatic Grade 3 QTc interval prolongation had ineligible baseline QTc values (Grade 2) and was withdrawn from the study. A total of 16 serious AEs were reported in 8 patients. 5 events in 4 patients were considered possibly or probably related to study drug: Grade 3 GI hemorrhage and duodenal ulcer in 1 patient, and Grade 3 pneumonia, Grade 4 pulmonary embolism, and Grade 2 haemoptysis.

About XL647

XL647 is a potent inhibitor of receptor tyrosine kinases (RTKs) that are implicated in driving tumor proliferation and vascularization (blood vessel formation). XL647 inhibits EGFR, HER2 and VEGFR2. The compound has been optimized for high potency and oral bioavailability (using in vivo systems), demonstrates excellent activity in target-specific cellular functional assays and has shown sustained inhibition of target RTKs preclinically in vivo following a single oral dose. Two phase 2 trials in patients with NSCLC are ongoing.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at <
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... March 27, 2015 Governor Andrew M. ... period for 43North - the world’s largest business idea ... grand prize of $1 million, six $500,000 awards and ... the world to compete for prizes that will turn ... the Western New York region. , "Last year's ...
(Date:3/26/2015)... March 26, 2015  BioNano Genomics, Inc., the leader ... Salyer as chief commercial officer. Salyer has more ... sales teams in life sciences. At BioNano, Salyer will ... a genome-mapping platform to assemble a comprehensive view of ... To date, 32 institutions located in the ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 "In America," the ... the United States that is hosted by legendary film actor ... topic of botany in an upcoming segment. , Botany ... in reality it is actually quite a bit more complicated ... of different types of living organisms, from the smallest bacteria ...
(Date:3/25/2015)... , March 25, 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... as a result of recent discussions with certain shareholders ... of the Company, after dealing with certain matters including ... meeting of shareholders on March 26, 2015 (the "Meeting") ... election of directors will take place when the Meeting ...
Breaking Biology Technology:Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 2SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 3SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 4SQI Diagnostics Inc. Announces New Nominees to SQI Diagnostics Board and Adjournment of Meeting 5
... March 23, 2011 Tengion, Inc. (Nasdaq: ... the addition of two renal research and clinical experts, ... from the Harvard Stem Cell Institute and ... & Development Advisors. This panel provides counsel to Tengion ...
... nanotubes dipped in a polymer solution equal the energy output ... of Case Western Reserve University engineers has found. The ... power output and maintain the other advantages by matching the ... they,ve proved the simple technique can knock down one of ...
... Spherix Incorporated (Nasdaq: SPEX), ... diabetes, metabolic syndrome and atherosclerosis; and providers of ... biotechnology and pharmaceutical companies, today announced that its ... the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference to be ...
Cached Biology Technology:Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 2Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 3Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 4Tengion Announces Addition of Two Renal Experts to Research & Development Advisors Panel 5Cheap catalyst made easy 2Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference 2Spherix to Present at the BIO-Windhover/Pharmaceutical Strategic Outlook 2011 Conference 3
(Date:3/23/2015)... NEW YORK , March 23, 2015   ... digital property management company, today announced that the Company ... platform for both enterprise and consumers at Connect:ID on ... D.C. HOYOS Labs will highlight the IEEE ... 1U TM ; and enterprise access control system. ...
(Date:3/20/2015)... , Mar. 20, 2015 Research and Markets ... addition of the "India Sensors Market Forecast ... The sensor market is projected to ... Consumer electronics, automotive, industrial and healthcare ... in the country. In addition, adoption of MEMS ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report to ... for Iris Biometrics in US$ Thousands. The report provides separate ... Japan , Europe , ... , and Latin America . ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... biomedical and health informatics, sent comments to the federal ... (DHHS/ ONCHIT), which has actively supported and incentivized the ... over the last year, and which solicited comment, through ... support for achieving meaningful use of EHRs in 2013 ...
... A new non-surgical post-mortem technique that has the ... the world has been pioneered by forensic pathologists and ... the University Hospitals of Leicester NHS Trust. The ... Forensic Pathology Unit, at the University of Leicester, has ...
... how farmers could protect themselves by growing a greater ... BioScience , has highlighted economical steps that farmers ... global climate change, including a greater frequency of extreme ... a policy priority for agriculture. The survey, by Brenda ...
Cached Biology News:AMIA on meaningful use: Invest in people and technology 2New non-surgical autopsy technique set to revolutionize post-mortem practice 2
... Concentrated x 10 This pH 9.9 ... prior to immunohistochemical staining procedures. It is ... mounted on glass slides. For particular antigens, ... especially effective. It should be noted that ...
... 9 (x 10) This product is ... heat-induced target retrieval prior to immunohistochemical staining ... formalin-fixed, paraffin-embedded tissue sections mounted on glass ... pH 6, the use of Target Retrieval ...
... Maximizer kit, 110 to 220 V, ... and doubles flow rates and valve ... The kit includes the Maximizer base ... kit, tubing kit, system cable 30, ...
MAb to Yersinia pestis F1 Ag. Yersinia pestis F1 Antigen EB Strain...
Biology Products: